Absci Corp
ABSI3.000USD
+0.100+3.45%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
382.62MCap. mercado
PérdidaP/E TTM
Más Datos de Absci Corp Compañía
Absci Corporation is a data-first generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. The Company’s Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, its Integrated Drug Creation platform aims to engineer biologics. It is developing a diversified portfolio of programs with a focus on cytokine biology. It has three wholly owned internal pipeline programs focusing on cytokine biology, as well as several other undisclosed pipeline programs under evaluation. Its wholly owned pipeline programs include ABS-101, ABS-201, and ABS-301. The Company’s other pipeline programs include ABS-501 and additional drug creation programs.
Información de la empresa
Símbolo de cotizaciónABSI
Nombre de la empresaAbsci Corp
Fecha de salida a bolsaJul 22, 2021
Director ejecutivoMr. Sean Mcclain
Número de empleados156
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 22
Dirección18105 Se Mill Plain Blvd
CiudadVANCOUVER
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal98683
Teléfono13609491041
Sitio Webhttps://www.absci.com/
Símbolo de cotizaciónABSI
Fecha de salida a bolsaJul 22, 2021
Director ejecutivoMr. Sean Mcclain
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sean Mcclain
Mr. Sean Mcclain
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
8.73M
+1.38%
Dr. Zachariah (Zach) Jonasson, Ph.D.
Dr. Zachariah (Zach) Jonasson, Ph.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
133.62K
-3.74%
Mr. Andreas Busch, Ph.D.
Mr. Andreas Busch, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
131.48K
+61.36%
Ms. Shelby J. Walker, J.D.
Ms. Shelby J. Walker, J.D.
Chief Legal Officer
Chief Legal Officer
59.30K
--
Ms. Karen K. Mcginnis, CPA
Ms. Karen K. Mcginnis, CPA
Independent Director
Independent Director
29.50K
+96.67%
Mr. Daniel A. (Dan) Rabinovitsj
Mr. Daniel A. (Dan) Rabinovitsj
Independent Director
Independent Director
14.50K
--
Ms. Mary T. Szela
Ms. Mary T. Szela
Director
Director
--
--
Mr. Frans Van Houten
Mr. Frans Van Houten
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Prof. Dr. Menelas (Mene) Pangalos, Ph.D.
Prof. Dr. Menelas (Mene) Pangalos, Ph.D.
Independent Director
Independent Director
--
--
Dr. Joseph Sirosh, Ph.D.
Dr. Joseph Sirosh, Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sean Mcclain
Mr. Sean Mcclain
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
8.73M
+1.38%
Dr. Zachariah (Zach) Jonasson, Ph.D.
Dr. Zachariah (Zach) Jonasson, Ph.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
133.62K
-3.74%
Mr. Andreas Busch, Ph.D.
Mr. Andreas Busch, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
131.48K
+61.36%
Ms. Shelby J. Walker, J.D.
Ms. Shelby J. Walker, J.D.
Chief Legal Officer
Chief Legal Officer
59.30K
--
Ms. Karen K. Mcginnis, CPA
Ms. Karen K. Mcginnis, CPA
Independent Director
Independent Director
29.50K
+96.67%
Mr. Daniel A. (Dan) Rabinovitsj
Mr. Daniel A. (Dan) Rabinovitsj
Independent Director
Independent Director
14.50K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 24 de jun
Actualizado: mar., 24 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
12.75%
ARK Investment Management LLC
6.97%
McClain (Sean)
6.05%
Redmile Group, LLC
5.72%
The Vanguard Group, Inc.
4.47%
Other
64.04%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
12.75%
ARK Investment Management LLC
6.97%
McClain (Sean)
6.05%
Redmile Group, LLC
5.72%
The Vanguard Group, Inc.
4.47%
Other
64.04%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
36.08%
Investment Advisor/Hedge Fund
18.18%
Individual Investor
6.46%
Hedge Fund
4.02%
Corporation
3.29%
Research Firm
1.79%
Bank and Trust
0.24%
Venture Capital
0.21%
Pension Fund
0.02%
Other
29.72%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
307
100.37M
69.60%
-3.07M
2025Q1
316
100.15M
78.58%
-546.74K
2024Q4
298
92.04M
80.13%
-8.74M
2024Q3
280
90.06M
79.27%
-8.98M
2024Q2
257
91.26M
83.61%
+4.72M
2024Q1
236
84.09M
77.41%
+14.50M
2023Q4
202
58.01M
62.41%
-6.63M
2023Q3
196
57.87M
62.40%
-7.67M
2023Q2
191
58.28M
63.02%
-12.48M
2023Q1
181
65.82M
71.20%
-6.10M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
18.39M
14.41%
+4.87M
+36.07%
Mar 31, 2025
ARK Investment Management LLC
10.96M
8.59%
+2.69M
+32.53%
Mar 31, 2025
McClain (Sean)
8.73M
6.84%
+119.00K
+1.38%
Mar 31, 2025
Redmile Group, LLC
8.25M
6.47%
--
--
Apr 25, 2025
The Vanguard Group, Inc.
4.69M
3.67%
-86.40K
-1.81%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.25M
4.9%
+325.67K
+5.50%
Mar 31, 2025
Phoenix Ventures Partners II LP.
4.75M
3.72%
-4.61M
-49.28%
Mar 31, 2025
Fred Alger Management, LLC
4.29M
3.37%
-2.21M
-33.99%
Mar 31, 2025
Columbia Wanger Asset Management, LLC
2.40M
1.88%
--
--
Mar 31, 2025
MFS Investment Management
2.31M
1.81%
+20.59K
+0.90%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ARK Genomic Revolution ETF
2.39%
WisdomTree BioRevolution Fund
0.95%
iShares Micro-Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Ver más
ARK Genomic Revolution ETF
Proporción2.39%
WisdomTree BioRevolution Fund
Proporción0.95%
iShares Micro-Cap ETF
Proporción0.06%
Invesco Nasdaq Biotechnology ETF
Proporción0.04%
ProShares Ultra Nasdaq Biotechnology
Proporción0.04%
iShares Biotechnology ETF
Proporción0.03%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0.01%
Schwab U.S. Small-Cap ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
